Arcellx Stock Soars 116% in Three Years: Is the Biotech Still a Buy at Current Levels?
Arcellx shares have delivered stellar multi-year gains, prompting investors to question if the rally still has room to run. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow models pointing to significant upside while price-to-book ratios suggest a more cautious stance.